Proactiveinvestors recommends

Additional Information

Market:	ASX
Sector:	Pharma & Biotech
EPIC:	QRX
Latest Price:	1.64 (2.82% )
52-week High:	2.39
52-week Low:	1.06
Market Cap:	236.46M

1 year chart

1 day chart

QRxPharma

QRxPharma Limited (ASX: QRX) is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and central nervous system (CNS) disorders.

The Company’s lead products comprise a patented combination of existing drugs, with a well-defined path to regulatory approval and sales. The Company’s preclinical and clinical pipeline includes other technologies in the fields of neurodegenerative disease and venomics.

QRxPharma inks agreement with TSX-listed Patheon

Monday, October 12, 2009 by Andrew McCrea

QRxPharma Limited (ASX: QRX, OTCQX: QRXPY) has added further value for shareholders, inking an agreement with Toronto listed Patheon Inc. (TSX: PTI) to manufacture clinical supplies of QRxPharma’s Dual-Opioid™ formulation (MoxDuo™CR).

Patheon is a leading contract drug developer and manufacturing for the pharmaceutical and biotechnology industries.

Patheon has a market capitalisation of C$180 million and revenues of US$717 million.

MoxDuo™CR is designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic).

The most advanced pain treatment product, MoxDuo™IR (immediate release formulation), is now in Phase 3 trials and scheduled for New Drug Application (NDA) filing with the US Food and Drug Administration in 2010.

“The Patheon relationship represents a major step forward for QRxPharma that rounds out our platform of MoxDuo™ products,” said Dr. John Holaday managing director.

“We are targeting a twice daily dosage with MoxDuo™ CR, and we anticipate our initial Phase 1 studies will begin this year to evaluate the pharmacokinetic profile of this patented formulation, Holaday said.”

QRxPharma’s formulation of MoxDuo™CR is anticipated to complete clinical trials in 2012.

The company believes MoxDuo™CR will deliver clinical benefits similar to those clinically demonstrated with MoxDuo™IR – fewer side effects and superior pain relief.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.